IU Health Krannert Personalized Medicine Study
Coronary Artery Disease
About this trial
This is an interventional health services research trial for Coronary Artery Disease focused on measuring Cytochrome P-450 CYP2C19, Pharmacogenetics, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention
Eligibility Criteria
Inclusion Criteria:
- Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy after percutaneous coronary intervention (PCI). Enrollment has to occur during index hospitalization or during outpatient visit for cath lab procedure.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Unwilling or unable, in the opinion of the investigator, to comply with instructions on prescribed medicines.
- Prior known allergy or intolerance to clopidogrel.
Sites / Locations
- Indiana University Health Methodist Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Pharmacogenetic Results Available to Provider
Control Arm
Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.